An ultrasensitive immunoassay for the detection of p-tau181 in blood
Yao Chen , Lei Chang, Kaj Blennow, Henrik Zetterberg, Andrew J. Ball
A high-sensitivity blood-based p-tau181 assay could potentially provide a valuable tool for Alzheimer’s disease (AD) research and drug discovery. Based on the recent publication from Karikari et al. [1], this new generation of p-tau181 Simoa™ assay was evaluated for sensitivity, parallelism, cross-reactivity to total tau, spike recovery, and analyte detectability in normal human serum, plasma and CSF and in plasma from Alzheimer’s Disease patients.
Development of an ultrasensitive multiplex assay for simultaneous detection of Aβ1-42, Aβ1-40, GFAP and NF-L in blood and CSF
Dandan Shan, Marcella Holdridge, Lei Chang, Erik Stoops, Inge M. W. Verberk, Wiesje van der Flier, Charlotte E. Teunissen, Andrew J. Ball
Previous work [1] has described plasma amyloid, GFAP and NF-L as predictors of Alzheimer’s pathology. Here we build on the Amyblood 1-42/1-40 Simoa™ assay [1,2] where GFAP and NF-L, as indicators of astrogliosis and neurodegeneration, further added to the prediction for Aβ PET imaging or diagnosis. We report a Simoa multiplex assay that simultaneously measures Aβ1-42, Aβ1-40, GFAP and NF-L in blood.
Related Posts
Next-Generation PhenoCode Molecular Barcoding Chemistry: Enhanced Reliability and Reproducibility for High-Plex Spatial Profiling
Poster Background Reliable and reproducible antibody barcoding is critical for spatial biology workflows onthe Akoya PhenoCycler®-Fusion 2.0 (PCF). We evaluated and optimized a complementarychemistry to the existing Antibody Conjugation Kit…
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…